This study discusses the evidence regarding buprenorphine dosing, noting the Food and Drug Administration’s (FDA) product label target dose of 16 mg/d. Early dose recommendations were based on mu receptor occupancy, and FDA buprenorphine literature states occupancy implies little difference between 16 and 24 mg. However, clinical studies demonstrate effectiveness at higher doses, including effects such as blocking the rewarding effects of opiate agonists, complete suppression of apnea from fentanyl, and improved treatment retention.

Full study: https://journals.lww.com/journaladdictionmedicine/pages/articleviewer.aspx?year=9900&issue=00000&article=00198&type=Fulltext